Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
Fundación Pública Andaluza para la investigación Biosanitaria de Andalucía oriental (FIBAO)
New Biomarkers and Technologies for Circulating Tumour Cells Identification and Isolation
A research group from Andalusian Public Health System (APHS) has identified
several biomarkers and developed new technology for improving CTCs isolation,
detection and characterization.
Metastasis is responsible for the vast majority of cancer-related deaths. During this process, circulating tumor cells (CTC) are generated, spread from the primary tumor, colonize distant
organs and lead to overt metastatic disease. During the past decade a growing interest in CTCs has spread out across the oncology field, especially looking at their capacity as prognostic
elements of cancer.
Despite important progresses in understanding and detecting CTCs, most of the assays still have low sensitivity; mainly due to the use of a few epithelial biomarkers to identify and isolate them from whole blood. EpCam and/or cytokeratins (CK) are
the two main epithelial biomarkers included in most of the devices used to date. Amongst those devices
However, recent evidences have demonstrated that a subset of
CTCs may lack EpCAM and cytokeratin expression and instead exhibit epithelial–mesenchymal transition (EMT) features.
Accordingly, the development of novel detection platforms should be accompanied by novel and specific CTC biomarkers that enhance their detection and molecular characterization.
Related links: